Efficacy of acellular pertussis vaccine in young infants.
A prospective study of a pertussis outbreak in a residential facility was done. Among 19 residents aged < or = 2 years, 10 children were unimmunized and 9 were immunized with acellular pertussis vaccines. Of the 10 unimmunized children, 7 acquired laboratory-confirmed pertussis (four-fold titer rise, positive culture, or both); of these, 6 developed typical symptoms. Eight of the 9 immunized children acquired laboratory-confirmed infections, and 1 of these developed typical symptoms. No difference in infection was noted between the unimmunized and immunized groups (7/10 vs. 8/9, respectively), but a significant difference was observed in the development of symptoms (6/10 vs. 1/9, P < .05). Also, the isolation rate of Bordetella pertussis seemed to differ between the two groups (6/10 vs. 2/9, P = .12). In this population, acellular pertussis vaccine did not prevent infection with B. pertussis but protected most young infants from the onset of clinical symptoms.
Aoyama
T
T
Department of Pediatrics, Kawasaki Municipal Hospital, Japan.
Iwata
T
T
Iwai
H
H
Murase
Y
Y
Saito
T
T
Akamatsu
T
T
D000907:Antibodies, Bacterial / Q000097:blood; D001886:Bordetella pertussis / Q000276:immunology / Q000302:isolation & purification*; D002675:Child, Preschool; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000008:administration & dosage / Q000276:immunology; D004196:Disease Outbreaks; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006388:Hemagglutinins / Q000276:immunology; D006801:Humans; D007117:Immunization, Secondary; D007223:Infant; D008297:Male; D009500:Neutralization Tests; D011446:Prospective Studies; D014611:Vaccination; D010566:Virulence Factors, Bordetella / Q000276:immunology; D014917:Whooping Cough / Q000453:epidemiology* / Q000517:prevention & control
D000907:Antibodies, Bacterial; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D006388:Hemagglutinins; D010566:Virulence Factors, Bordetella